Novel Triple Agonist BI 3034701 (GLP-1/GIP/NPY2) Enters Phase 2, Targeting Central Hunger Control
Key Questions
What is BI 3034701 and how does it differ from existing GLP-1 therapies?
BI 3034701 is a first-in-class triple receptor agonist (GLP-1/GIP/NPY2) entering Phase 2, with the NPY2 component targeting central appetite regulation. This differentiates it from standard incretin-based drugs.
What is the current development status of BI 3034701?
Boehringer Ingelheim has initiated a Phase 2 trial after acceptable Phase 1 safety results, with EUR 10M milestone paid to partner Gubra. Phase 2 data is expected in coming years.
Why is the NPY2 receptor target significant in obesity treatment?
The NPY2 component adds a novel mechanism focused on central hunger control, expanding beyond incretin pathways. It represents an addition to the obesity pharmacotherapy pipeline with potential for differentiated efficacy.
Boehringer Ingelheim initiates Phase 2 trial of BI 3034701, a first-in-class triple receptor agonist developed by Gubra. The NPY2 component targets central appetite regulation, differentiating it from incretin-based therapies. Phase I safety acceptable. EUR 10M milestone paid to Gubra. Phase 2 data expected in coming years. This adds a novel mechanism to the obesity pharmacotherapy pipeline.